Three of the innovators in the use of CRISPR-Cas9 were Emmanuelle Charpentier, Jennifer Doudna, and Feng Zhang. Doudna and Zhang helped to launch Editas Medicine in 2013, but Doudna left the following year that joined Therapeutic Intellia.
Intellia Therapeutics is currently receiving a valuation of over $ 700 million. Editas is worth over $ 1.3 billion. As a top scientist and co-discovery of CRISPR, Jennifer Doudna has a lot of shares in Editas and Intellia.
Incredibly, Doudna released a statement condemning the controversial genes of human embryos.
It is vital that this news does not detract from the important clinical efforts to use CRISPR technology to treat and improve diseases in adults and children. Much of the genome editing technology uses in many public domains must continue, as is happening over the next three days at the Genome Editing Genome Summit in Hong Kong.
Editing human genes of embryos is extremely controversial. A large shareholder in CRISPR companies collects any controversial use of CRISPR that could trigger any objection against the CRISPR business.